Pages that link to "Q40650613"
Jump to navigation
Jump to search
The following pages link to Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. (Q40650613):
Displaying 10 items.
- ABCB1 genetic variants in leukemias: current insights into treatment outcomes (Q33707782) (← links)
- Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues (Q37061957) (← links)
- Advances and challenges in hereditary cancer pharmacogenetics (Q38948499) (← links)
- The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. (Q45790127) (← links)
- Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism (Q47134737) (← links)
- Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. (Q51251518) (← links)
- The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients (Q58588447) (← links)
- Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer (Q86967231) (← links)
- Could polymorphisms in ABCB1 gene represent a genetic risk factor for the development of mammary tumors in dogs? (Q92196255) (← links)
- Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine-N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients (Q99711975) (← links)